Can You Give Flotera to a 6-Month-Old Baby?
Yes, Flotera (Lactobacillus reuteri) can be safely given to a 6-month-old infant, as multiple studies have demonstrated its safety profile in infants as young as 1 month of age, and the FDA-approved dosing is three pellets dissolved under the tongue three times daily. 1, 2, 3
Safety Profile in Young Infants
L. reuteri DSM 17938 has been extensively studied in infants starting at 1 month of age with no severe adverse events reported across multiple randomized controlled trials. 4, 5
A 2017 safety trial specifically evaluated L. reuteri in infants aged 3 weeks to 3 months and found it safe even in infants with neutropenia (low white blood cell counts), which frequently coexists with colic. 4
The 2014 systematic review confirmed there are no safety concerns regarding the use of L. reuteri in non-immunocompromised subjects, including preterm infants. 3
FDA-Approved Dosing
The standard dose is three pellets dissolved under the tongue three times per day, as specified in the FDA drug label for Flotera. 1
For infants who cannot dissolve pellets under the tongue, parents can dissolve the pellets in a small amount of liquid (breast milk, formula, or water) and administer via spoon or dropper, though this is an off-label modification of the approved route.
Evidence-Based Indications in 6-Month-Olds
Functional constipation:
- A 2010 randomized controlled trial in infants ≥6 months with chronic constipation showed L. reuteri significantly increased bowel movement frequency at weeks 2,4, and 8 compared to placebo (P=0.042, P=0.008, P=0.027 respectively). 2
Acute gastroenteritis:
- A 2025 trial demonstrated L. reuteri reduced diarrhea duration (2.77 vs 3.10 days, P=0.036) and decreased watery stool frequency in children 1 month to 5 years of age. 6
- However, the 2020 AGA guidelines suggest against routine probiotic use for acute infectious gastroenteritis in children based on moderate-quality evidence. 7
Antibiotic-associated diarrhea prevention:
- A 2026 systematic review found L. reuteri DSM 17938 reduced AAD risk when administered for up to 21 days (RR 0.50,95% CI 0.33-0.75), particularly in children receiving amoxicillin-clavulanate. 8
Important Clinical Caveats
When NOT to use:
- Do not use in immunocompromised infants without pediatric infectious disease consultation, as probiotic safety data are limited in this population. 3
- Avoid in critically ill infants or those with central venous catheters due to theoretical risk of probiotic bacteremia, though this has not been reported with L. reuteri specifically. 7
Condition-specific considerations:
- For infantile colic, evidence is mixed: L. reuteri appears effective in exclusively breastfed infants but not in formula-fed infants. 3, 9
- A 2014 Australian community-based trial found no benefit for colic in a mixed feeding population, with the probiotic group actually crying/fussing 49 minutes MORE than placebo at 1 month (P=0.02). 9
Practical Administration Tips
- Ensure the product contains the specific strain DSM 17938 (or NCIMB 30351), as probiotic effects are strain-specific. 3, 5
- Administer at consistent times each day to maintain steady colonization. 1
- No refrigeration is typically required for most L. reuteri formulations, but verify product-specific storage requirements. 1
- Monitor for any signs of allergic reaction (rash, difficulty breathing, swelling), though these are exceedingly rare. 3